211 related articles for article (PubMed ID: 37720688)
21. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
[TBL] [Abstract][Full Text] [Related]
22. Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies.
Hernandez C; Arasanz H; Chocarro L; Bocanegra A; Zuazo M; Fernandez-Hinojal G; Blanco E; Vera R; Escors D; Kochan G
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244396
[TBL] [Abstract][Full Text] [Related]
23. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.
Trovato R; Fiore A; Sartori S; Canè S; Giugno R; Cascione L; Paiella S; Salvia R; De Sanctis F; Poffe O; Anselmi C; Hofer F; Sartoris S; Piro G; Carbone C; Corbo V; Lawlor R; Solito S; Pinton L; Mandruzzato S; Bassi C; Scarpa A; Bronte V; Ugel S
J Immunother Cancer; 2019 Sep; 7(1):255. PubMed ID: 31533831
[TBL] [Abstract][Full Text] [Related]
24. Persistent accumulation of circulating monocytic myeloid-derived suppressor cells contributes to post-infectious immunosuppression in renal transplant recipients with bacterial infection: A pilot study.
Jiang Y; Feng S; Ji J; Lin Z; Zhang X
Transpl Immunol; 2018 Jun; 48():10-17. PubMed ID: 29477752
[TBL] [Abstract][Full Text] [Related]
25.
Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
[TBL] [Abstract][Full Text] [Related]
26. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Hubert P; Roncarati P; Demoulin S; Pilard C; Ancion M; Reynders C; Lerho T; Bruyere D; Lebeau A; Radermecker C; Meunier M; Nokin MJ; Hendrick E; Peulen O; Delvenne P; Herfs M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33712445
[TBL] [Abstract][Full Text] [Related]
27. Early Posttransplant Mobilization of Monocytic Myeloid-derived Suppressor Cell Correlates With Increase in Soluble Immunosuppressive Factors and Predicts Cancer in Kidney Recipients.
Utrero-Rico A; Laguna-Goya R; Cano-Romero F; Chivite-Lacaba M; Gonzalez-Cuadrado C; Rodríguez-Sánchez E; Ruiz-Hurtado G; Serrano A; Fernández-Ruiz M; Justo I; González E; Andrés A; Paz-Artal E
Transplantation; 2020 Dec; 104(12):2599-2608. PubMed ID: 32068661
[TBL] [Abstract][Full Text] [Related]
28. Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma.
Zhao Q; Huang L; Qin G; Qiao Y; Ren F; Shen C; Wang S; Liu S; Lian J; Wang D; Yu W; Zhang Y
Cancer Lett; 2021 Oct; 518():35-48. PubMed ID: 34139285
[TBL] [Abstract][Full Text] [Related]
29. Tumor-infiltrating monocytic myeloid-derived suppressor cells contribute to the development of an immunosuppressive tumor microenvironment in gastric cancer.
Tsutsumi C; Ohuchida K; Katayama N; Yamada Y; Nakamura S; Okuda S; Otsubo Y; Iwamoto C; Torata N; Horioka K; Shindo K; Mizuuchi Y; Ikenaga N; Nakata K; Nagai E; Morisaki T; Oda Y; Nakamura M
Gastric Cancer; 2024 Mar; 27(2):248-262. PubMed ID: 38217732
[TBL] [Abstract][Full Text] [Related]
30. Stroke-Induced Modulation of Myeloid-Derived Suppressor Cells (MDSCs) and IL-10-Producing Regulatory Monocytes.
Achmus L; Ruhnau J; Grothe S; von Sarnowski B; Bröker BM; Dressel A; Schulze J; Vogelgesang A
Front Neurol; 2020; 11():577971. PubMed ID: 33329318
[No Abstract] [Full Text] [Related]
31. Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma.
Sun SH; Benner B; Savardekar H; Lapurga G; Good L; Abood D; Nagle E; Duggan M; Stiff A; DiVincenzo MJ; Suarez-Kelly LP; Campbell A; Yu L; Wesolowski R; Howard H; Shah H; Kendra K; Carson WE
Front Immunol; 2021; 12():740890. PubMed ID: 34712230
[TBL] [Abstract][Full Text] [Related]
32. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
33. Myeloid-Derived Suppressor Cells and CD68
Lv M; Zhuang X; Shao S; Li X; Cheng Y; Wu D; Wang X; Qiao T
J Immunol Res; 2022; 2022():3621496. PubMed ID: 35928634
[TBL] [Abstract][Full Text] [Related]
34. Modified method for differentiation of myeloid-derived suppressor cells
Zhou H; Xie Z; Morikawa N; Sakurai F; Mizuguchi H; Okuzaki D; Okada N; Tachibana M
Biochem Biophys Rep; 2023 Mar; 33():101416. PubMed ID: 36605123
[TBL] [Abstract][Full Text] [Related]
35. B7H3-dependent myeloid-derived suppressor cell recruitment and activation in pulmonary fibrosis.
Liu T; Gonzalez De Los Santos F; Rinke AE; Fang C; Flaherty KR; Phan SH
Front Immunol; 2022; 13():901349. PubMed ID: 36045668
[TBL] [Abstract][Full Text] [Related]
36. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
Hou A; Hou K; Huang Q; Lei Y; Chen W
Front Immunol; 2020; 11():783. PubMed ID: 32508809
[TBL] [Abstract][Full Text] [Related]
37. Surgery-induced monocytic myeloid-derived suppressor cells expand regulatory T cells in lung cancer.
Wang J; Yang L; Yu L; Wang YY; Chen R; Qian J; Hong ZP; Su XS
Oncotarget; 2017 Mar; 8(10):17050-17058. PubMed ID: 28178645
[TBL] [Abstract][Full Text] [Related]
38. Myeloid-derived suppressor cells in peripheral blood as predictive biomarkers in patients with solid tumors undergoing immune checkpoint therapy: systematic review and meta-analysis.
Möller M; Orth V; Umansky V; Hetjens S; Braun V; Reißfelder C; Hardt J; Seyfried S
Front Immunol; 2024; 15():1403771. PubMed ID: 38855104
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients.
Van Wigcheren GF; De Haas N; Mulder TA; Horrevorts SK; Bloemendal M; Hins-Debree S; Mao Y; Kiessling R; van Herpen CML; Flórez-Grau G; Hato SV; De Vries IJM
Oncoimmunology; 2021; 10(1):1935557. PubMed ID: 34239773
[TBL] [Abstract][Full Text] [Related]
40. The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis.
Bronte G; Calabrò L; Olivieri F; Procopio AD; Crinò L
Clin Exp Med; 2023 Sep; 23(5):1551-1561. PubMed ID: 36401744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
